ArticleInternational journal of dermatology2026
Effect of Belimumab on the Cutaneous Manifestations of Patients With Lupus Erythematosus.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe aim was to assess the long-term effect of belimumab on the cutaneous manifestations of patients with systemic lupus erythematosus (SLE).
methodsThe retrospective analysis included 29 patients with SLE. Cutaneous disease activity was assessed using the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) activity scores before treatment with belimumab and at 3, 6, 12, and up to 60 months of treatment. Eleven patients were treated for the whole observation period; however, only 8 patients were evaluable at 48 months, and only 6 at 60 months due to loss of follow-up.
resultsCompared to the baseline score, a significant reduction of the CLASI and RCLASI activity score was seen during the treatment (mean CLASI baseline 8.76 ± 5.12, after 3 months 5.59 ± 3.87, p < 0.001, after 60 months 4.67 ± 3.86, p = 0.017; mean RCLASI baseline 10.93 ± 6.57, after 3 months 7.62 ± 6.03, after 60 months 5.33 ± 4.31, p = 0.012). The percentage of patients achieving a CLASI 100 response increased continuously over time, reaching a maximum of 30% after 60 months. Response was most remarkable among patients with acute or discoid cutaneous lupus. The treatment was well tolerated by the patients, with the most common adverse events being respiratory infections, headaches, and arthralgia, among others.
conclusionThis retrospective analysis demonstrated that belimumab has long-term benefits for cutaneous manifestations of patients with lupus erythematosus. However, prospective studies in larger patient populations are needed to confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.